万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://onlinelibrary.wiley.com/journal/14683083
3、投稿网址：http://mc.manuscriptcentral.com/jeadv
4、官网邮箱：jeadv@eadv.org（编辑部）
asao.sarukawa@eadv.org（编辑部）
5、官网电话：
+41 91 973 45 20; +41 91 973 45 30（编辑部）
6、期刊刊期：月刊，一年出版12期。
2021年6月2日星期三
投稿须知【官网信息】
Author Guidelines
1. AIMS & SCOPE
The Journal of the European Academy of Dermatology and Venereology(JEADV) is the official publication of the European Academy of Dermatology and Venereology (EADV). The JEADV is one of the leading international peer-reviewed journals in the field of Dermatology and Venereology. Our target audience is clinician dermatologists in hospitals or in private practice, as well as researchers and everybody interested in understanding the management of skin disease to improve patient outcomes.
The aim of the JEADV is to deliver the highest level of dermatological knowledge to its readership, publishing clinical and translational research articles, clinical trial reports, and systematic and state of the art reviews. The Journal publishes original articles, review articles, short reports, and also welcomes submissions of Letters to the Editor expressing opinions on current and/or controversial issues as well as observations of general importance. With thought-provoking features like editorials, commentaries and the Historical Perspectives series, the Journal strives to be an engaging and relevant platform for dermatologists and venereologists in Europe and beyond.
Furthermore, the JEADV is the place where the European Clinical Guidelines derived from cooperation between the European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the Union Européenne des Médecins Spécialistes (UEMS), and other relevant subspecialty societies are published.
2. MANUSCRIPT CATEGORIES
JEADV invites the following types of submissions:
Original Articles.
Original Articles are the Journal’s primary mode of communication. This type of manuscripts should report new data arising out of scientific research that may involve a wide range of empirical methods and study designs. Original articles must include a structured abstract (maximum 300 words), and should not exceed 3000 words of body text (that is, excluding the abstract, reference list and figure legends). The addition of tables and figures (with figure legends) is encouraged.
Clinical Trial Registration. As of January 2020, JEADV requires that clinical trials are prospectively registered in a publicly accessible trials registry. We ask authors to provide the name of the trial register and the clinical trial registration number at the end of the abstract. The journal considers a trial for publication only if it has been registered prior to randomization of patients. If the trial is not registered, or was registered retrospectively, justification for this should be given when submitting the manuscript.
Reporting standards. Manuscripts reporting randomised controlled trials (RCTs) must follow the CONSORT statement. RCTs will not be considered by JEADV without submission of a completed CONSORT checklist. Checklists should be uploaded during manuscript submission using file designation 'Supplementary files for review'.
Review Articles. The Journal is particularly keen to publish concise, high-quality review articles identifying, synthesizing and summarizing available evidence about a focused topic pertaining to clinical practice and discussing recent advances in laboratory or clinical research. The JEADV welcomes the submission of both systematic and narrative reviews. Systematic reviews and meta-analyses are published under the Systematic Review subcategory within Review Articles. Review articles may be submitted by authors for publication subject to peer review or may be solicited by the Editor-in-Chief. Review articles must include an unstructured abstract (maximum 300 words), and should not exceed 5000 words of body text. Use of tables and figures (with figure legends) is encouraged.
Systematic Review Registration. Prospective registration of systematic reviews on PROSPERO or a similar database is recommended.
Reporting standards. Reports of systematic reviews and meta-analyses must include a completed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram to accompany the main text. Checklists should be uploaded during manuscript submission using file designation 'Supplementary files for review'. Authors are encouraged to include an assessment of the methodological quality of the included studies.
Short Reports. Brief data papers on very new findings are published as short reports. Short reports must include a structured abstract and should not exceed 1500 words of body text, 4 figures/tables and 20 references.
Letters to the Editor. Letters to the Editor (Correspondence) may be in response to issues arising from recently published articles, or short, free-standing pieces expressing an opinion. Case reports will be considered and published as Letters to the Editor if they represent an outstanding contribution to the treatment of a specific skin disorder or provide new clinical information. Letters to the Editor should not have an abstract, should be formatted in one continuous section (no subheadings) and should not exceed 600 words, 10 references and a total of 2 visual elements, i.e. 2 figures; or 2 tables; or 1 figure and 1 table. No supplementary material (figure, table or text) is allowed when submitting a Letter to the Editor. All letters are published online-only, although they are each published as a part of a specific issue.
Book Reviews. The Journal publishes reviews of recent books in Dermatology and Venereology and in related fields. Book reviews are solicited by the Editor-in-Chief. Proposals with adequate information on the book may also be submitted by prospective book reviewers. All book reviews are subject to expert review.
3. SUBMISSION OF MANUSCRIPTS
All submissions should be made online at the JEADVScholarOne ManuscriptsTM site: https://mc.manuscriptcentral.com/jeadv
New users should first create an account. Once a user is logged onto the site, submissions should be made via the Author Dashboard. Authors must also supply:
(i) completed Conflicts of Interest Disclosure form(s)—JEADV employs the ICMJE conflicts of interest disclosure form. The ICMJE form can be downloaded here: ICMJE Form. Each listed author must complete the form electronically. It is the responsibility of all corresponding authors to upload—on behalf of all co-authors— the completed forms as ‘COI form’ via ScholarOne ManuscriptsTM at the same time as the manuscript submission. Manuscripts will not be sent for peer-review without these forms. (See section 6 for further information.)
4. CONTACTING THE EDITORIAL OFFICE
Asao Sarukawa, Head of Editorial and Publication – JEADV
EADV Headquarters, Via S. Balestra 22 B, 6900 Lugano, Switzerland
Tel: +41 91 973 45 20; Email: jeadv@eadv.org
5. PREPARATION OF MANUSCRIPTS
Manuscripts must be submitted in grammatically correct English (American or British usage is accepted, but not a mixture of the two). Manuscripts that do not meet this standard cannot be reviewed. Authors for whom English is a second language may wish to consider having their manuscript professionally edited before submission to improve the English. A list of independent suppliers of editing services can be found at http://authorservices.wiley.com/bauthor/english_language.asp. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.
The main text of each manuscript should be supplied in a format compatible with Word (.doc or .docx). Do not submit text saved in PDF format (.pdf). Tables and flow charts are considered textual and should also be supplied in a format compatible with Word. Tables and flow charts submitted in TIFF, JPG, PDF or PowerPoint files are NOT acceptable. Figures must be uploaded as separate figure files in appropriate formats (see section Formats). All manuscripts must be typed in 12 pt font with margins of at least 2.5 cm. Submissions must comply with the word limits defined in section 2 and, where appropriate, please include:
Title page. A title page must be provided for all submissions regardless of the type of manuscript being submitted. Please note that without title page, the submission will not be sent to peer-review and will be instantly returned to the authors so they can update their submission. The first page of all manuscripts should contain the following information:
1. the title of the paper
2. a list of key words (2–6 article key words)
3. manuscript word, table and figure count
4. names of authors as initial(s) followed by surnames
5. names of the institutions at which the research was conducted, clearly linked to respective authors
6. name, address, telephone and fax number, and email address of corresponding author
7. a statement of all funding sources that supported the work
8. any conflict of interest disclosures (see sections 3 and 6).
Number of authors. The JEADV does not have an upper limit concerning the number of authors of a manuscript. Please note that the ScholarOne ManuscriptsTM site allows submitting agents to add a maximum of 15 authors for each submitted manuscript, however, this is in every case overwritten by the list of authors provided on the Title page.
Abstracts. Authors submitting original articles or short reports should note that structured abstracts are required. The structured abstract should adopt the format: Background, Objectives, Methods, Results, Conclusions.
Review articles require abstracts but they should not be structured, namely, they should not have subheadings. Letters to the Editor do not require abstracts. Abstracts should contain no citations to previously published work.
Text. The main text of a manuscript should in general, but not necessarily, be divided into sections with the headings: Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Legends and Figures.
Tables and figures. Tables and figures should not be inserted in the appropriate place in the text but should be provided as separate files and should be uploaded below the main text.
Tables and figures should be referred to in text as follows: Fig. 1, Figs 2–4; Table 1, Table 2. The place at which a table or figure is to be inserted in the printed text should be indicated clearly in the manuscript. A title should be provided for each table. Where a figure has more than one panel, each panel should be labelled in the top left-hand corner using lower case letters in parentheses, i.e., (a), (b), etc., and a brief description of each panel given in the figure legend.
Colour illustrations are welcomed and all colour is published free of charge to the author.
Authors are themselves responsible for obtaining permission to reproduce previously published materials (e.g. figures, diagrams, charts, tables, etc.), for which they do not own the copyright. Permissions must be obtained from the original publisher or copyright holder and the evidence must be provided to the Editorial Office. You must acknowledge the original source in the figure/table legends, as requested by the original publisher. When an individual is identifiable in a photograph or human neuroimaging data and brain scans are presented, written permission must be obtained (see section 6).
Figure legends. Each figure must have a legend that explains its purpose without reference to the text. Figure legends should be listed in numerical order, at the end of the text document, separate from the figure files. Please note that Figure legends are excluded from the word count.
Formats. Clinical photographs may be supplied in GIF, JPEG, PNG, or TIFF format at the time of submission, but only TIFF files (and exceptionally JPEG files, as original format) are suitable for production and printing. JEADV has a dedicated medical illustrator who works on accepted manuscripts to format/re-design the tables/figures to comply with the Journal's style. If a manuscript is accepted, the corresponding author will be contacted to provide high-quality photographs at their actual size, which is 100% of their print dimension in TIFF format, at a minimum resolution of 300 pixels per inch and in RGB color mode.
Vector graphics (e.g. graphs, diagrams, histograms) should be provided in editable PPT, PDF, EPS, or AI files, either in greyscales or RGB at the appropriate resolutions: 300 dpi for color figures; 600 for black and white figures; 1200 dpi for line-art figure.
Tables should be supplied in a format compatible with Word, preferably as .DOC files. The authors are requested to ensure that the whole area of the tables is visible in the PDF proof of the manuscript.
Flow charts should be provided in an editable Word format.
Images and photographs destined to redesigns should not contain any added lettering (a,b,c,..), arrows or symbols.
If submitting artwork electronically, please read the information at: http://authorservices.wiley.com/bauthor/illustration.asp
Patient consent. For papers that include information or images which could identify or potentially identify individuals, authors must obtain a consent form which the patient, parent or guardian must sign by acknowledging the potential of publication and their awareness of the content. The signed consent form should be filed securely in the patient's case notes and the manuscript submitted to JEADV should include this statement in the Acknowledgment section indicating that specific consent for publication was obtained: "The patients in this manuscript have given written informed consent to publication of their case details.” The journal editorial office will not collect or archive consent forms from authors, but reserves the right to enquire about or audit their presence.
References. References should be in Vancouver format and appear as consecutive, unbracketed superscript numbers in the text, e.g., ‘in our previous reports1,2 and those of Smith et al.3–5 and should be listed numerically in the reference list at the end of the article.
Format references as below, using standard (Medline) abbreviations for journal titles. If more than six authors, include the first three authors followed by et al. If six or fewer authors, please include all authors' names.
1. de Berker DAR, Baran R, Dawber RPR. The nail in dermatological diseases. In: Baran and Dawber's Diseases of the Nails and their Management(Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, eds), 3rd edn. Oxford: Blackwell Science Ltd, 2001; 172–92.
2. Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol2008;22:1–6.
3. Graham-Brown R, Burns T. Lecture Notes: Dermatology. Oxford: Wiley-Blackwell, 2006.
4. British Lymphology Society. Consensus Document on the Management of Cellulitis in Lymphoedema. 2007.
Available at: http://www.lymphoedema.org/lsn/consensus_on_cellulitis_dec_06.pdf(last accessed 28 November 2007).
……
更多详情：
https://onlinelibrary.wiley.com/page/journal/14683083/homepage/forauthors.html
